HIV and the menopause

Menopause International

Volumn 14, Issue 4, 2008, Pages 163-168

  Fan, Maria D ^a   Maslow, Bat Sheva ^a   Santoro, Nanette ^a   Schoenbaum, Ellie ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Bone density; cardiovascular diseases; cognition; HIV; menopause

Indexed keywords

HORMONE;

BONE DENSITY; CARDIOVASCULAR DISEASE; COGNITION; GERIATRICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE; REVIEW; SYMPTOMATOLOGY; CHEMICALLY INDUCED DISORDER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; CARDIOVASCULAR DISEASES; COGNITION; FEMALE; HIV INFECTIONS; HUMANS; MENOPAUSE; MIDDLE AGED; RISK FACTORS;

EID: 61549108664     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2008.008027     Document Type: Review

References (75)

1. Palella F, Jr, Delaney K, Moorman A,, et al Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60
2. Bhaskaran K, Hamouda O, Sannes M,, et al Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51–9
3. Zapantis G, Santoro N. The menopausal transition: characteristics and management. Best Pract Res Clin Endocrinol Metab 2003; 17: 33–52
4. Nelson HD. Menopause. Lancet 2008; 371: 760–70
5. Miller SA, Santoro N, Lo Y,, et al Menopause symptoms in HIV-infected and drug-using women. Menopause 2005; 12: 348–56
6. Centers for Disease Control and Prevention. Twenty-five years of HIV/AIDS – United States, 1981–2006. MMWR 2006; 55: 585–9
7. Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol 1998; 8: 229–35
8. Kritz-Silverstein D, Barrett-Connor E. Early menopause, number of reproductive years, and bone mineral density in postmenopausal women. Am J Public Health 1993; 83: 983–8
9. Snowdon DA, Kane RL, Beeson WL,, et al Is early natural menopause a biologic marker of health and aging? Am J Public Health 1989; 79: 709–14
10. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404–11
11. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003; 157: 923–9
12. Hu FB, Grodstein F, Hennekens CH,, et al Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159: 1061–6
13. Cejtin H, Kalinowski A, Bacchetti P,, et al Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol 2006; 108: 1423–31
14. Schoenbaum EE, Hartel D, Lo Y,, et al HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005; 41: 1517–24
15. Ferreira CE, Pinto-Neto AM, Conde DM,, et al Menopause symptoms in women infected with HIV: prevalence and associated factors. Gynecol Endocrinol 2007; 23: 198–205
16. Clark RA, Cohn SE, Jarek C,, et al Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr 2000; 23: 99–100
17. Gold EB, Bromberger J, Crawford S,, et al Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153: 865–74
18. Fantry LE, Zhan M, Taylor GH,, et al Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS 2005; 19: 703–11
19. Torgerson DJ, Avenell A, Russell IT,, et al Factors associated with onset of menopause in women aged 45–49. Maturitas 1994; 19: 83–92
20. Bromberger JT, Matthews KA, Kuller LH,, et al Prospective study of the determinants of age at menopause. Am J Epidemiol 1997; 145: 124–33
21. Johnson TM, Cohen HW, Howard AA,, et al Attribution of menopause symptoms in human immunodeficiency virus-infected or at-risk drug-using women. Menopause 2008; 15: 551–7
22. Gold EB, Colvin A, Avis N,, et al Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006; 96: 1226–35
23. World Health Organization. Report of a WHO Scientific Group. Research on the Menopause in the 1990s. Technical Report Series 866; 1996
24. Soules MR, Sherman S, Parrott E,, et al Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001; 76: 874–8
25. Santoro N. The menopausal transition. Am J Med 2005; 118(Suppl. 128): 8–13
26. Santoro N, Arnsten JH, Buono D,, et al Impact of street drug use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-aged women. J Womens Health (Larchmt) 2005; 14: 898–905
27. Santoro N, Lo Y, Moskaleva G,, et al Factors affecting reproductive hormones in HIV-infected, substance-using middle-aged women. Menopause 2007; 14: 859–65
28. Yin MT, Glesby MJ. Low bone mineral density, HIV infection, and women: fracture or fiction? Clin Infect Dis 2006; 42: 1021–3
29. Dolan SE, Huang JS, Killilea KM,, et al Reduced bone density in HIV-infected women. AIDS 2004; 18: 475–83
30. Yin M, Dobkin J, Brudney K,, et al Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005; 16: 1345–52
31. Arnsten JH, Freeman R, Howard AA,, et al HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42: 1014–20
32. Yun AJ, Lee PY. Maldaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. Med Hypotheses 2004; 63: 532–7
33. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 2000; 35: 947–56
34. McComsey GA, Kendall MA, Tebas P,, et al Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21: 2473–82
35. Adeyemi O. Cardiovascular risk and risk management in HIV-infected patients. Top HIV Med 2007; 15: 159–62
36. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother 2008; 61: 238–45
37. Martin Lde S, Pasquier E, Roudaut N,, et al Metabolic syndrome: a major risk factor for atherosclerosis in HIV-infected patients (SHIVA study). Presse Med 2008; 37: 579–84
38. Schillaci G, De Socio GV, Pucci G,, et al Aortic Stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension 2008; 52: 308–13
39. Currier JS, Havlir DV. Complications of HIV disease and therapy. Top HIV Med 2007; 15: 40–47
40. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther 2006; 13: 248–60
41. Baril JG, Junod P, Leblanc R,, et al HIV-associated lipodystrophy syndrome: a review of clinical aspects. Can J Infect Dis Med Microbiol 2005; 16: 233–43
42. Grundy SM, Brewer HB, Jr, Cleeman JI,, et al Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–8
43. Dolan SE, Hadigan C, Killilea KM,, et al Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39: 44–54
44. Rexrode KM, Carey VJ, Hennekens CH,, et al Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843–8
45. Sobieszczyk ME, Hoover DR, Anastos K,, et al Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immun Defic Syndr 2008; 48: 272–80
46. Triant VA, Lee H, Hadigan C,, et al Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506–12
47. Klein D, Hurley L, Silverberg M,, et al eds. Surveillance data for myocardial infarction hospitalizations among HIV+ and HIV− Northern Californians: 1994–2006. Circulation 2008; 118: e29–e35
48. Wildman RP, Colvin AB, Powell LH,, et al Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women's Health Across the Nation (SWAN). Menopause 2008; 15: 414–21
49. Jensen-Urstad K, Jensen-Urstad M, Johansson J. Carotid artery diameter correlates with risk factors for cardiovascular disease in a population of 55-year-old subjects. Stroke 1999; 30: 1572–6
50. Sowers MR, Matthews KA, Jannausch M,, et al Hemostatic factors and estrogen during the menopausal transition. J Clin Endocrinol Metab 2005; 90: 5942–8
51. Mohamad MJ, Karayyem M, Mohammad MA,, et al Serum sex hormones in premenopausal women with coronary heart disease. Neuro Endocrinol Lett 2006; 27: 758–62
52. Sutton-Tyrrell K, Wildman RP, Matthews KA,, et al Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242–9
53. Sowers MR, Jannausch M, Randolph JF,, et al Androgens are associated with hemostatic and inflammatory factors among women at the mid-life. J Clin Endocrinol Metab 2005; 90: 6064–71
54. Rosano GM, Vitale C, Marazzi G,, et al Menopause and cardiovascular disease: the evidence. Climacteric 2007; 10(Suppl. 1):19–24
55. Gohlke-Barwolf C. Coronary artery disease: is menopause a risk factor? Basic Res Cardiol 2000; 95(Suppl. 1):I77–83
56. Matthews KA, Kuller LH, Sutton-Tyrrell K,, et al Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 2001; 32: 1104–11
57. Kok HS, Kuh D, Cooper R,, et al Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause 2006; 13: 19–27
58. Halbreich U, Lumley LA, Palter S,, et al Possible acceleration of age effects on cognition following menopause. J Psychiatr Res 1995; 29: 153–63
59. Herlitz A, Thilers P, Habib R. Endogenous estrogen is not associated with cognitive performance before, during, or after menopause. Menopause 2007; 14: 425–31
60. Fuh JL, Wang SJ, Lee SJ,, et al A longitudinal study of cognition change during early menopausal transition in a rural community. Maturitas 2006; 53: 447–53
61. Drake EB, Henderson VW, Stanczyk FZ,, et al Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology 2000; 54: 599–603
62. Lebrun CE, van der Schouw YT, de Jong FH,, et al Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol (Oxf) 2005; 63: 50–55
63. Yonker JE, Eriksson E, Nilsson LG,, et al Sex differences in episodic memory: minimal influence of estradiol. Brain Cogn 2003; 52: 231–8
64. Whalley LJ, Fox HC, Starr JM,, et al Age at natural menopause and cognition. Maturitas 2004; 49: 148–56
65. Genazzani AR, Pluchino N, Luisi S,, et al Estrogen, cognition and female ageing. Hum Reprod Update 2007; 13: 175–87
66. Spencer JL, Waters EM, Romeo RD,, et al Uncovering the mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol 2008; 29: 219–37
67. Craig MC, Murphy DG. Oestrogen, cognition and the maturing female brain. J Neuroendocrinol 2007; 19: 1–6
68. U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002; 137: 834–9
69. Alexander JL, Sommer BR, Dennerstein L,, et al Role of psychiatric comorbidity on cognitive function during and after the menopausal transition. Expert Rev Neurother 2007; 7(Suppl. 11):S157–80
70. Vance DE, Burrage JW. Promoting successful cognitive aging in adults with HIV: strategies for intervention. J Gerontol Nurs 2006; 32: 34–41
71. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4: 543–55
72. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007; 27: 86–92
73. Vance DE, Struzick TC. Addressing risk factors of cognitive impairment in adults aging with HIV: a social work model. J Gerontol Soc Work 2007; 49: 51–77
74. Julg B, Goebel FD. Treatment interruption in HIV therapy: a SMART strategy? Infection 2006; 34: 186–8
75. Lieberman R. HIV in older Americans: an epidemiologic perspective. J Midwifery Womens Health 2000; 45: 176–82